July 24, 2024 07:35 AM EDTUpdated 02:50 PM
R&D

Pfiz­er touts Phase 3 gene ther­a­py da­ta in he­mo­phil­ia A, but now it needs to prove it can win the mar­ket

Lei Lei Wu

News Reporter

Can Pfiz­er do what Bio­Marin couldn’t in he­mo­phil­ia A?

Pfiz­er an­nounced Wednes­day that its gene ther­a­py for he­mo­phil­ia A met the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times